Vascular endothelial growth factor (VEGF) is a signalling protein which boosts the development of new blood vessels. VEGF forms a portion of this mechanism which restores the blood flow to cells when they're deprived of blood because of compromised blood flow.
Among the chief functions of VEGF would be to produce new blood vessels because a baby grows and develops in the uterus. This protein also stimulates the development of new blood vessels following trauma as well as the rise of muscle following exercise was performed. The Human Vascular Endothelial Growth Factor or VEGF ELISA equipment quantitates VEGF present in human serum, plasma etc.
The assay will only comprehend both natural and recombinant Hu VEGF. In circumstances where blood vessels have been blocked, VEGF also boosts the introduction of new blood vessels to bypass cells. Vascular Endothelial Growth Factor (VEGF), initially called vascular permeability factor (VPF), is a family of proteins which excite vasculogenesis and angiogenesis.
VEGF165 is a 45 KDa homodimeric glycoprotein and contains moderate affinity to heparin. In contrast, VEGF 121 does not bind heparin. VEGF specifically binds tyrosine kinase receptors VEGFR-1 (Flt-1) and also VEGFR-2 (Flk-1) to trigger downstream signaling pathways resulting in endothelial cell survival, proliferation, migration, and vascular permeability. VEGF plays a vital role in normal vascular reproductive and bronchial angiogenesis.
On the other hand, VEGF is fundamental to pathological angiogenesis by improving vessel permeability or recruitment endothelial progenitor cells to remote sites of neovascularization. The nicely comprehension of VEGF in boosting pathological angiogenesis and tumor metastasis has resulted in the rational research on obstructing the VEGF/VEGFR axis in preventing angiogenesis and tumor growth in several clinical versions.